Anne Letessier

Dr. Anne Letessier

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDavid Rombaut
David Rombaut
CLCarine Lefèvre
Carine Lefèvre
TRTony Rached
Tony Rached
SBSabrina Bondu
Sabrina Bondu
ALAnne Letessier
Anne Letessier
MFMichaela Fontenay
Michaela Fontenay
Myelodysplastic syndromes (MDS) with mutated SF3B1 gene present features including a favourable outcome distinct from MDS with mutations in other splicing factor genes SRSF2 or U2AF1. Molecular bases of these divergences are poorly understood. Here we find that SF3B1-mutated MDS show reduced R-loop formation predominating in gene bodies associated with intron retention reduction, not found in U2AF1- or SRSF2-mutated MDS. Compared to erythroblasts from SRSF2- or U2AF1-mutated patients, SF3B1-mutated erythroblasts exhibit augmented DNA synthesis, accelerated replication forks, and single-stranded DNA exposure upon differentiation. Importantly, histone deacetylase inhibition using vorinostat restores R-loop formation, slows down DNA replication forks and improves SF3B1-mutated erythroblast differentiation. In conclusion, loss of R-loops with associated DNA replication stress represents a hallmark of SF3B1-mutated MDS ineffective erythropoiesis, which could be used as a therapeutic target.

29 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Maud de DieuleveultMaud de Dieuleveult
Maud de Dieuleveult
CMClaire Marchal
Claire Marchal
AJAnne Jouinot
Anne Jouinot
ALAnne Letessier
Anne Letessier
Benoit MiottoBenoit Miotto
Benoit Miotto
Prostate cancer is one of the most commonly diagnosed cancers in men. A number of genomic and clinical studies have led to a better understanding of prostate cancer biology. Still, the care of patients as well as the prediction of disease aggressiveness, recurrence and outcome remain challenging. Here, we showed that expression of the gene ZBTB38 is associated with poor prognosis in localised prostate cancer and could help discriminate aggressive localised prostate tumours from those who can benefit only from observation. Analysis of different prostate cancer cohorts indicates that low expression levels of ZBTB38 associate with increased levels of chromosomal abnormalities and more aggressive pathological features, including higher rate of biochemical recurrence of the disease. Importantly, gene expression profiling of these tumours, complemented with cellular assays on prostate cancer cell lines, unveiled that tumours with low levels of ZBTB38 expression might be targeted by doxorubicin, a compound generating reactive oxygen species. Our study shows that ZBTB38 is involved in prostate cancer pathogenesis and may represent a useful marker to identify high risk and highly rearranged localised prostate cancer susceptible to doxorubicin.

24 May 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MWManon Watzky
Manon Watzky
SHSolène Huard
Solène Huard
LJLudmila Juricek
Ludmila Juricek
JDJulien Dairou
Julien Dairou
CCCaroline Chauvet
Caroline Chauvet
Benoit MiottoBenoit Miotto
Benoit Miotto
The aryl hydrocarbon receptor (AHR) regulates the expression of numerous genes in response to activation by agonists including xenobiotics. Although it is well appreciated that environmental signals and cell intrinsic features may modulate this transcriptional response, how it is mechanistically achieved remains poorly understood. We show that hexokinase 2 (HK2) a metabolic enzyme fuelling cancer cell growth, is a transcriptional target of AHR as well as a modulator of its activity. Expression of HK2 is positively regulated by AHR upon exposure to agonists both in human cells and in mice lung tissues. Conversely, over-expression of HK2 regulates the abundance of many proteins involved in the regulation of AHR signalling and these changes are linked with altered AHR expression levels and transcriptional activity. HK2 expression also shows a negative correlation with AHR promoter methylation in tumours, and these tumours with high HK2 expression and low AHR methylation are associated with a worse overall survival in patients. In sum, our study provides novel insights into how AHR signalling is regulated which may help our understanding of the context-specific effects of this pathway and may have implications in cancer.

14 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Benoit MiottoBenoit Miotto
Benoit Miotto
MGMorgane Le Gall
Morgane Le Gall
ALAnne Letessier
Anne Letessier
Genes encoding BAH-domain proteins play important roles in many physiological and pathological cellular processes via the recognition of methylated substrates. We systematically analyzed the transcription levels of these genes, as well as their association with clinical and molecular features, in 31 cancer types. Our analysis revealed the potential prognostic value of BAH-containing genes in many cancers, notably that high levels of ORC1 expression are significantly associated with both shorter overall and disease-free survival in adrenocortical carcinoma, brain lower grade glioma, liver hepatocellular carcinoma, and sarcoma. We further observed that these tumors with high levels of ORC1 share several commonalities independently of their tissue of origin. High levels of ORC1 expression are notably associated with pathways related to cell proliferation and pluripotency-related networks, as well as mutation burden, chromosomal alterations, and aneuploidy, to different extents. We further identified a set of common master and upstream molecular regulators in tumors with high ORC1 expression in these different tumor types as well as computationally predicted therapeutic compounds. We thus provide a resource focused on BAH-containing genes that may help distinguish tumors with poor outcomes while also highlighting mechanistic, prognostic, and therapeutic features across different cancer types.

15 November 2022 in Blood
Verified
Journal Article
Open access
DRDavid Rombaut
David Rombaut
CLCarine Lefevre
Carine Lefevre
BFBatoul Farhat
Batoul Farhat
SBSabrina Bondu
Sabrina Bondu
ALAnne Letessier
Anne Letessier
MFMichaela Fontenay
Michaela Fontenay
Introduction: Myelodysplastic syndromes (MDS) with SF3B1 mutation represent a subtype of hematopoietic stem cell disorders with bone marrow (BM) erythroid dyspl